

Channavix Executive Summary

Channavix is a start-up biotech company dedicated to the discovery of novel therapeutics for neurological disorders such as pain. Our mission is to improve patient pain management by developing local, targeted, long-lasting and non-addictive painkillers. Our proprietary technology relies on new biological insights and a new unique mechanism of action, leading to innovative therapies for pain management. Our studies have shown that our products provide up to 3 weeks of analgesia after a single administration.

Current pain treatments have shown to be of either limited efficacy or fraught with adverse side effects and/or addiction potential. There is a critical unmet need for the development of novel, non-opioid, non-addicting analgesics. The Food and Drug Administration is encouraging the development of non-addictive pain treatment therapies with the use of Fast Track and Breakthrough Therapy designations.

Channavix, was founded by Drs. Elsa Daurignac and Arin Bhattacharjee, State University of New York at Buffalo. Channavix participated in the National Science Foundation I-Corps Site Program at the University at Buffalo and has ongoing advisement/support from the Critical Path Accelerator Program, University at Buffalo Technology Incubator.

Channavix has developed novel, small lipidated peptides that are locally delivered to the painful area. Our novel lipidated peptides penetrate pain neurons endings and remain inside them. The peptides target key ion channels and their transport mechanisms, preventing pain signals from being generated. They are tethered to the inner surface of the neuronal membrane and are protected from proteolytic degradation resulting in long-lasting effects.

Patent filings on these peptides are in place. In addition, proof-of-concept studies and limited preliminary preclinical studies have been completed. The technology has also been supported by peer-review scientific publications.

We have multiple lead candidates for chronic pain (arthritis, migraine, neuropathy) and acute post-operative pain. The estimated target US annual market potential is \$69.18 billion. Our goals are to optimize the formulation, delivery and dosing of our lead candidates. We also need to complete pre-clinical work, including extended pharmacokinetic and toxicity studies which will allow for the filing of an Investigational New Drug (IND) application to the FDA. Channavix is looking for investors/partners to support the current and future development of these assets.